Even after controlling for a person’s existing substance use and mental health disorders, there remained a 3.5-fold increased ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Scientists have known for decades that the classic symptoms of schizophrenia, such as jumping to conclusions or difficulty ...

Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...

By Puyaan Singh and Bhanvi Satija (Reuters) -AbbVie shares fell over 12% on Monday after an experimental schizophrenia drug ...

A new study from ICES and University of Ottawa reveals a 21-fold increase in schizophrenia risk following emergency visits ...

A new study links hallucinogen-related emergency department visits to a 21-fold increased risk of schizophrenia compared to ...

Walton said she lived with undiagnosed schizophrenia since she was young ... It's been difficult to see how her face has changed since the surgery, and she said she sometimes doesn't recognize ...

Schizophrenia is a mental health disorder that ... With long-term use, tardive dyskinesia can develop and may be permanent. Your face may move involuntarily, such as blinking a lot or sticking ...

AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...

ED visits related to hallucinogen use are linked to a 21-fold increased risk of schizophrenia spectrum disorder, results of a ...

AbbVie Inc. shares fell the most in more than four years after two mid-stage trials of its drug to treat schizophrenia failed ...